Clinical Trial Update: A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions [Phase 1]

View source ↗

Summary

Phase 1 PET imaging study of an mGluR5 tracer across several neuropsychiatric conditions has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Autism Spectrum Disorder
• Cognitive Impairment
• Fragile Syndrome
• Huntington Disease
• Parkinson Disease

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Parkinson Disease, Huntington Disease | Phase 1 | Status: COMPLETED